BCAA Composition for TBI-Related Memory Recovery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Traumatic brain injury (TBI) causes long-lasting cognitive impairment and memory dysfunction due to regional imbalances in excitatory and inhibitory synaptic activity, with altered neuronal and astrocytic metabolism, and current therapies are ineffective.

Innovation Solution

Administering branched chain amino acids (BCAAs), particularly valine, leucine, and isoleucine, either orally or in compositions with pharmaceutically acceptable carriers, to inhibit and treat TBI-related pathologies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current therapies are used for TBI, then treatment is provided, but they are ineffective in mitigating or rectifying cognitive impairment and memory dysfunction

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidcognitive function recovery

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent changes the biochemical parameters of the brain by administering branched chain amino acids (valine, leucine, isoleucine) to alter amino acid levels in the hippocampus. This biochemical parameter change restores cognitive function and memory by normalizing the metabolic state following TBI, directly addressing the ineffectiveness of current therapies.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If BCAA administration is implemented, then cognitive function and memory are improved, but the mechanism of action is not fully understood

Engineering Contradiction:

Improvememory encoding functionVSAvoidmechanism understanding

Core Design Contradiction:

ProductivityVSDifficulty of detecting and measuring

Solution Approach 1:

The patent utilizes feedback from measuring hippocampal amino acid levels to determine the effectiveness of BCAA administration. By monitoring changes in amino acid concentrations and correlating them with cognitive improvement, the patent establishes a feedback loop that helps understand the mechanism while demonstrating therapeutic benefit.

Inventive Principle:

Principle #23Feedback

3Reliability

If TBI occurs, then brain injury is sustained, but long-lasting cognitive impairment and memory dysfunction result

Engineering Contradiction:

Improvebrain injury recoveryVSAvoidduration of cognitive impairment

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent administers BCAAs in the preliminary phase following TBI to prevent the development of long-lasting cognitive impairment. By intervening early in the recovery process, the treatment addresses metabolic disruptions before they lead to enduring dysfunction, thereby reducing the duration of cognitive impairment.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent converts the harmful metabolic disruption caused by TBI into a beneficial therapeutic opportunity. By administering BCAAs that target the specific metabolic alterations (increased lactate, increased intracellular glutamate), the treatment transforms the injury-induced metabolic state into a pathway for recovery and cognitive improvement.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20260053765A1Compositions and methods for the improvement of memory

Publication Date: 2026.02.26 THE CHILDRENS HOSPITAL OF PHILADELPHIA

AI summary

Compositions and methods are provided for the improvement of memory.